Pharmaceuticals, Biotechnology and Life Sciences
Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3…
Conference Call and Webcast Scheduled for Wednesday, May 11, 2022, at 4:30 p.m. EasternSAN DIEGO and GAINESVILLE, Ga., May 04,…
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First…
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered…
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated…
Generated $12.1 million in Q1 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesReported 18-month data with intravitreal pegcetacoplan in geographic atrophy…
Achieved Oxbryta® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong…
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a…
– Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC –…
Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual MeetingHighly significant ~75% reduction in hypoglycemia events at anticipated therapeutic…